Devra J Olson

Abstract 1140: Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer

Lauren Farr, E. Trueblood, S. Sandall, 2022, Cancer Research.

1187 Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors

A. Nesterova, T. Lewis, Taisuke Nakazawa, 2022, Regular and Young Investigator Award Abstracts.

Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers

A. Nesterova, T. Lewis, Bernard A. Liu, 2020 .

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

A. Nesterova, T. Lewis, N. Okeley, 2023, Molecular cancer therapeutics.